相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。OPTN/SRTR 2018 Annual Data Report: Kidney
A. Hart et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis
Natalia Lucia Rukavina Mikusic et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2020)
Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation
Edouard Bonneville et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Pharmacogenetic-Whole blood and intracellular pharmacokinetic-Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients
Camille Tron et al.
PLOS ONE (2020)
Gut microbial diversity, inflammation, and oxidative stress are associated with tacrolimus dosing requirements early after heart transplantation
Douglas L. Jennings et al.
PLOS ONE (2020)
Clinical Implications of Unique Drug Interaction Between Extended Release Tacrolimus and Phenytoin
Taylor M. Harkness et al.
PROGRESS IN TRANSPLANTATION (2020)
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19)
Marilu Bartiromo et al.
TRANSPLANT INFECTIOUS DISEASE (2020)
Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant
Ibtissem Hannachi et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2020)
Treatment of prolonged tacrolimus toxicity using phenytoin in a haemodialysis patient
Calvin J. Meaney et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2019)
Prior Amiodarone Exposure Reduces Tacrolimus Dosing Requirements in Heart Transplant Recipients
Nadine T. Breslin et al.
PROGRESS IN TRANSPLANTATION (2019)
Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients
Zheng Lu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients
Paolo Gallo et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2019)
Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation
Akira Mimura et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2019)
Marked change in blood tacrolimus concentration levels due to grapefruit in a renal transplant patient
Xingyu Zhai et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2019)
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Merce Brunet et al.
THERAPEUTIC DRUG MONITORING (2019)
Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients
Chi Yuen Cheung et al.
TRANSPLANTATION PROCEEDINGS (2019)
Characterizing the pharmacokinetics and pharmacodynamics of immunosuppressant medicines and patient outcomes in elderly renal transplant patients
Amelia R. Cossart et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2019)
Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients
Aleixandra Mendoza Rojas et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
Nassim Kamar et al.
ADVANCES IN THERAPY (2019)
A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients
L. M. Andrews et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation
Camille Tron et al.
CLINICAL PHARMACOKINETICS (2019)
Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites
Yukuang Guo et al.
DRUG METABOLISM AND DISPOSITION (2019)
Effects of MDR1 1236C > T-2677G > T-3435C > T polymorphisms on the intracellular accumulation of tacrolimus, cyclosporine A, sirolimus and everolimus
Rong Wang et al.
XENOBIOTICA (2019)
Effect of CYP3A5 genotype on hospitalization cost for kidney transplantation
Suda Vannaprasaht et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2019)
Identification of Antibiotic Administration as a Potentially Novel Factor Associated With Tacrolimus Trough Variability in Kidney Transplant Recipients: A Preliminary Study
YuanPu Zheng et al.
TRANSPLANTATION DIRECT (2019)
Outcomes Following Macrolide Use in Kidney Transplant Recipients
Rachel Jeong et al.
CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE (2019)
Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients
W. S. Oetting et al.
PHARMACOGENOMICS JOURNAL (2018)
Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers
Babar Bashir et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients
Olivia Campagne et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability
Litaty Cephanoee Mbatchi et al.
PHARMACOGENOMICS (2018)
Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype
Nuria Lloberas et al.
PHARMACOGENOMICS (2018)
A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation
Sandar Min et al.
PEDIATRIC TRANSPLANTATION (2018)
The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates
Claudio Franceschi et al.
FRONTIERS IN MEDICINE (2018)
Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation
Scott Davis et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation
Louise M. Andrews et al.
CLINICAL PHARMACOKINETICS (2018)
A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMET™ Plus platform
Y. Choi et al.
PHARMACOGENOMICS JOURNAL (2017)
Kidney Transplant in a Human Immunodeficiency Virus-Positive Patient: Case Report of Drug Interactions
Mümtaz Yılmaz et al.
Experimental and Clinical Transplantation (2017)
Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients
Fei Liu et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2017)
Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity
Kristyna Krasulova et al.
MOLECULES (2017)
Genotype-based tacrolimus dosing guidelines: with or without CYP3A4☆22?
Laure Elens et al.
PHARMACOGENOMICS (2017)
Tacrolimus: Does direct glucuronidation matter? An analytical and pharmacological perspective
Camille Tron et al.
PHARMACOLOGICAL RESEARCH (2017)
An Atlas of β-Glucuronidases in the Human Intestinal Microbiome
Rebecca M. Pollet et al.
STRUCTURE (2017)
Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients
Thomas Vanhove et al.
THERAPEUTIC DRUG MONITORING (2017)
Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4
Andreas H. Groll et al.
TRANSPLANT INFECTIOUS DISEASE (2017)
High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime
Henry R. Whalen et al.
TRANSPLANTATION (2017)
Tacrolimus Increases the Effectiveness of Itraconazole and Fluconazole against Sporothrix spp.
Luana P. Borba-Santos et al.
FRONTIERS IN MICROBIOLOGY (2017)
Interleukin-6 Induces DEC1, Promotes DEC1 Interaction with RXRα and Suppresses the Expression of PXR, CAR and Their Target Genes
Rui Ning et al.
FRONTIERS IN PHARMACOLOGY (2017)
Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation
Jean-Baptiste Woillard et al.
FRONTIERS IN PHARMACOLOGY (2017)
Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients
Jean-Baptiste Woillard et al.
CLINICAL PHARMACOKINETICS (2017)
Molecular and physiological manifestations and measurement of aging in humans
Sadiya S. Khan et al.
AGING CELL (2017)
A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach
Franc Andreu et al.
CLINICAL PHARMACOKINETICS (2017)
Advagraf®, a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts
Sophie Caillard et al.
TRANSPLANT INTERNATIONAL (2016)
Colchicine-Induced Myopathy in a Tacrolimus-Treated Renal Transplant Recipient: Case Report and Literature Review
Zeenat Yousuf Bhat et al.
AMERICAN JOURNAL OF THERAPEUTICS (2016)
High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients
T. Vanhove et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation
N. Shuker et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations
J. T. Tang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients
Camille Tron et al.
JOURNAL OF CHROMATOGRAPHY A (2016)
Effect of Intestinal Flora on Protein Expression of Drug-Metabolizing Enzymes and Transporters in the Liver and Kidney of Germ-Free and Antibiotics-Treated Mice
Takuya Kuno et al.
MOLECULAR PHARMACEUTICS (2016)
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Peter Spanogiannopoulos et al.
NATURE REVIEWS MICROBIOLOGY (2016)
CYP3A4 intronic SNP rs35599367 (CYP3A4☆22) alters RNA splicing
Danxin Wang et al.
PHARMACOGENETICS AND GENOMICS (2016)
Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study
Martine De Meyer et al.
PHARMACOGENOMICS (2016)
Pharmacokinetic and pharmacodynamic changes in older adults and implications for palliative care
Leah Sera et al.
PROGRESS IN PALLIATIVE CARE (2016)
Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations
N. Pallet et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation
Carlos Orlando Jacobo-Cabral et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
K. A. Birdwell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients
Beatriz Tavira et al.
JOURNAL OF HUMAN GENETICS (2015)
Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients
Sarah Leyking et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
The Functional Implications of Common Genetic Variation in CYP3A5 and ABCB1 in Human Proximal Tubule Cells
Noel Knops et al.
MOLECULAR PHARMACEUTICS (2015)
African-American Race Modifies the Influence of Tacrolimus Concentrations on Acute Rejection and Toxicity in Kidney Transplant Recipients
David J. Taber et al.
PHARMACOTHERAPY (2015)
Developmental Regulation of Drug-Processing Genes in Livers of Germ-Free Mice
Felcy Pavithra Selwyn et al.
TOXICOLOGICAL SCIENCES (2015)
A Rationale for Age-Adapted Immunosuppression in Organ Transplantation
Felix Krenzien et al.
TRANSPLANTATION (2015)
Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation
L. Yessayan et al.
TRANSPLANTATION PROCEEDINGS (2015)
Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies
L. Rojas et al.
PHARMACOGENOMICS JOURNAL (2015)
The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients
H. de Jonge et al.
PHARMACOGENOMICS JOURNAL (2015)
Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation
John R. Lee et al.
PLOS ONE (2015)
Inflammation-Induced Phenoconversion of Polymorphic Drug Metabolizing Enzymes: Hypothesis with Implications for Personalized Medicine
Rashmi R. Shah et al.
DRUG METABOLISM AND DISPOSITION (2015)
Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus
Henrike Bruckmueller et al.
THERAPEUTIC DRUG MONITORING (2014)
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks
Laure Elens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women
Flavia Franconi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer
King Leung Fung et al.
CANCER RESEARCH (2014)
The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation
Dennis A. Hesselink et al.
CLINICAL PHARMACOKINETICS (2014)
Colchicine levels in chronic kidney diseases and kidney transplant recipients using tacrolimus
Anara Amanova et al.
CLINICAL TRANSPLANTATION (2014)
Importance of hematocrit for a tacrolimus target concentration strategy
Elisabet Storset et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
Ingrid Lunde et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach
Bojana Golubovic et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
The Proton Pump Inhibitor Lansoprazole, but not Rabeprazole, the Increased Blood Concentrations of Calcineurin Inhibitors in Japanese Patients with Connective Tissue Diseases
Kentaro Isoda et al.
INTERNAL MEDICINE (2014)
Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure
Ruth Sapir-Pichhadze et al.
KIDNEY INTERNATIONAL (2014)
ABCB1 1199G>A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines
Geraldine Dessilly et al.
PLOS ONE (2014)
Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients
Mateusz Kurzawski et al.
PHARMACOGENETICS AND GENOMICS (2014)
P450 Oxidoreductase*28 ( POR*28) and Tacrolimus Disposition in Pediatric Kidney Transplant Recipients-A Pilot Study
Violette M. G. J. Gijsen et al.
THERAPEUTIC DRUG MONITORING (2014)
Effects of Elevated Tacrolimus Trough Levels in Association With Infectious Enteritis on Graft Function in Renal Transplant Recipients
A. Nakamura et al.
TRANSPLANTATION PROCEEDINGS (2014)
Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients
Lynda Frassetto et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2013)
The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations
Laure Elens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Effect of CYP3A5*3 Polymorphism on Pharmacokinetic Drug Interaction between Tacrolimus and Amlodipine
Xiao-cong Zuo et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients
Nayoung Han et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients
Wei Zhao et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients
Dan-ying Li et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Pomegranate-containing products and tacrolimus: A potential interaction
Tam Khuu et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2013)
Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation
Matthew D. Hickey et al.
LIVER TRANSPLANTATION (2013)
Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2013)
Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation
Luis E. Rojas et al.
PHARMACOGENETICS AND GENOMICS (2013)
Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2013)
Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis
Xiao-cong Zuo et al.
PHARMACOGENETICS AND GENOMICS (2013)
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
Laure Elens et al.
PHARMACOGENOMICS (2013)
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin
Laure Elens et al.
PHARMACOGENOMICS (2013)
CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients
Violette M. G. J. Gijsen et al.
PHARMACOGENOMICS (2013)
Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Henry J. Haiser et al.
SCIENCE (2013)
Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines
Laure Elens et al.
THERAPEUTIC DRUG MONITORING (2013)
Long-Term Impact of Immunosuppressants at Therapeutic Doses on Male Reproductive System in Unilateral Nephrectomized Rats: A Comparative Study
Yehui Chen et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence
J. Sellares et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo
Kathrin Klein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal Transplantation
I. A. Hauser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
A Simultaneous D-Optimal Designed Study for Population Pharmacokinetic Analyses of Mycophenolic Acid and Tacrolimus Early After Renal Transplantation
Flora Tshinanu Musuamba et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation
Martine De Meyer et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Pharmacogenetics in Kidney Transplantation Recent Updates and Potential Clinical Applications
Laure Elens et al.
MOLECULAR DIAGNOSIS & THERAPY (2012)
A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient
Michelle Maguire et al.
PEDIATRIC TRANSPLANTATION (2012)
The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis
Salvatore Terrazzino et al.
PHARMACOGENETICS AND GENOMICS (2012)
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients
Kelly A. Birdwell et al.
PHARMACOGENETICS AND GENOMICS (2012)
Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients
Yi Li et al.
TRANSPLANT IMMUNOLOGY (2012)
Effect of Mild Diarrhea on Tacrolimus Exposure
Gerben A. J. van Boekel et al.
TRANSPLANTATION (2012)
Risk of Tacrolimus Toxicity in CYP3A5 Nonexpressors Treated With Intravenous Nicardipine After Kidney Transplantation
David K. Hooper et al.
TRANSPLANTATION (2012)
Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations - twice daily Prograf® and once daily Advagraf®
Jean-Baptiste Woillard et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers
Alissa J. Wright et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2011)
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
Laure Elens et al.
CLINICAL CHEMISTRY (2011)
Age-Related Changes in Pharmacokinetics
Shaojun Shi et al.
CURRENT DRUG METABOLISM (2011)
Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis
X. -J. Shi et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2011)
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)
Laura M. Hodges et al.
PHARMACOGENETICS AND GENOMICS (2011)
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients
Laure Elens et al.
PHARMACOGENOMICS (2011)
The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients
Hylke de Jonge et al.
PHARMACOGENOMICS (2011)
Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective
J-L Li et al.
PHARMACOGENOMICS JOURNAL (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
In Vitro Investigation of Human UDP-Glucuronosyltransferase Isoforms Responsible for Tacrolimus Glucuronidation: Predominant Contribution of UGT1A4
Isabelle Laverdiere et al.
DRUG METABOLISM AND DISPOSITION (2011)
Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation
Khaled Benkali et al.
CLINICAL PHARMACOKINETICS (2010)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
E. Thervet et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients
Ping Wang et al.
PHARMACOGENOMICS (2010)
CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation
Arnaud Capron et al.
PHARMACOGENOMICS (2010)
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Bret D. Wallace et al.
SCIENCE (2010)
Elevated Tacrolimus Levels Associated With Intravenous Azithromycin and Ceftriaxone: A Case Report
M. A. Shullo et al.
TRANSPLANTATION PROCEEDINGS (2010)
Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients
Khaled Benkali et al.
CLINICAL PHARMACOKINETICS (2009)
Sex Differences in Pharmacokinetics and Pharmacodynamics
Offie P. Soldin et al.
CLINICAL PHARMACOKINETICS (2009)
Drug Interaction Between Tacrolimus and Carbamazepine in a Japanese Heart Transplant Recipient: A Case Report
Kyoichi Wada et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2009)
Cytochrome P450-mediated metabolism in the human gut wall
Kirstin Thelen et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2009)
Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts
Maarten Naesens et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test
Beatrice Oneda et al.
PHARMACOGENETICS AND GENOMICS (2009)
Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: Fact or fiction?
Stefanie Lam et al.
ANNALS OF PHARMACOTHERAPY (2008)
Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity
Andrea DiMartini et al.
LIVER TRANSPLANTATION (2008)
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
Dennis A. Hesselink et al.
PHARMACOGENETICS AND GENOMICS (2008)
Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1l2 and their association with CYP3A4 expression
Jatinder Lamba et al.
DRUG METABOLISM AND DISPOSITION (2008)
1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2007)
The current state of knowledge on age, sex, and their interactions on clinical pharmacology
J. B. Schwartz
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
ABCB1 genotype and PGP expression, function and therapeutic drug response:: a critical review and recommendations for future research
G. D. Leschziner et al.
PHARMACOGENOMICS JOURNAL (2007)
Drugs as CYP3A probes, inducers, and inhibitors
Yi-Tong Liu et al.
DRUG METABOLISM REVIEWS (2007)
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study
Elina Teicher et al.
CLINICAL PHARMACOKINETICS (2007)
CAR and PXR: The xenobiotic-sensing receptors
Yoav E. Timsit et al.
STEROIDS (2007)
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates:: Guidelines from an experimental study
V. Haufroid et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients - Ciclosporin, tacrolimus and levofloxacin in renal transplantation
S Federico et al.
CLINICAL PHARMACOKINETICS (2006)
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
DX Wang et al.
PHARMACOGENETICS AND GENOMICS (2005)
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus
LK Kamdem et al.
CLINICAL CHEMISTRY (2005)
Cytochrome p450 3A4 and p-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea
W Lemahieu et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Effects of pomegranate juice on human cytochrome P450 3A (CYP3A) and carbamazepine pharmacokinetics in rats
M Hidaka et al.
DRUG METABOLISM AND DISPOSITION (2005)
Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and south Asians
IAM MacPhee et al.
TRANSPLANTATION (2005)
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
V Haufroid et al.
PHARMACOGENETICS (2004)
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic-polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients
K Sato et al.
CLINICAL TRANSPLANTATION (2004)
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation
D Anglicheau et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Drug-drug interaction mediated by inhibition and induction of P-glycoprotein
JH Lin
ADVANCED DRUG DELIVERY REVIEWS (2003)
Structural determinants of P-glycoprotein-mediated transport of glucocorticoids
CR Yates et al.
PHARMACEUTICAL RESEARCH (2003)
Increased transcriptional activity of the CYP3A4* 1B promoter variant
B Amirimani et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2003)
The influence of sex on pharmacokinetics
JB Schwartz
CLINICAL PHARMACOKINETICS (2003)
Drug interactions with tacrolimus
T van Gelder
DRUG SAFETY (2002)
Mechanisms of clinically relevant drug interactions associated with tacrolimus
U Christians et al.
CLINICAL PHARMACOKINETICS (2002)
Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: Pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect
T Minematsu et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Evaluation of the genetic component of variability in CYP3A4 activity:: a repeated drug administration method
V Özdemir et al.
PHARMACOGENETICS (2000)
分享论文
